Fortress Biotech, Inc.(FBIO)Stock Analysis

FBIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Fortress Biotech, Inc. (FBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FBIO at 61.8/100 on a 32-signal composite quality model, placing it at rank #788 of 2,879 stocks — the top half of the AI-ranked universe. FBIO scores in the top quartile across balance sheet strength (99.8), free cash flow (97.5), profitability (97.3). Areas of concern include institutional flow (5.9) and revenue scale (12.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Fortress Biotech, Inc. reports quarterly revenue of $16.0M, net income of $110.4M, an operating margin of -48.3%. Top institutional holders of FBIO by reported 13-F value include Opaleye Management, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. FBIO trades on the Nasdaq exchange and files with the SEC under CIK 1429260. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Fortress Biotech, Inc. directly from SEC EDGAR. Fortress Biotech, Inc.'s 13F Pro composite quality score has ranged between 9 and 63 since 2021, currently 61.8 — an improving long-term trajectory across 28 quarterly and live scoring snapshots.